Mononuclear Therapeutics Passed AABB Assessment

Mononuclear Therapeutics Ltd (MonoTx™) in Hong Kong has passed regular assessment of American Association of Blood Banks (AABB) experts for its cellular therapy activities, including collection, processing, storage and distribution of umbilical cord blood stem cells, such as hematopoietic stem cells and mononuclear cells, and received the “Certificate of Accreditation” and “Cellular Starting Material Qualification”.

MonoTx™ has maintained the accreditations since 2019 and has established an umbilical cord blood mononuclear cell (UCBMNC) bank to provide lifesaving cellular products. MonoTx™ is developing regenerative therapies using UCBMNC and other components to treat neurological disorders and other diseases.